Prevention and management of antineoplastic extravasation injury

Hospital Pharmacy

Volumn 35, Issue 1, 2000, Pages 57-74

  Mullin, Sbantel ^a   Christina Beckwith, M ^a   Tyler, Linda S ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Adverse reaction; Antineoplastic agents; Chemotherapy; Extravasation; Intravenous administration; Vesicant

Indexed keywords

AMONAFIDE; AMSACRINE; ANTINEOPLASTIC AGENT; BISANTRENE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYTARABINE; DACARBAZINE; DAUNORUBICIN DERIVATIVE; DOCETAXEL; DOXORUBICIN; ECHINOMYCIN; EPIRUBICIN; ESORUBICIN; ETOPOSIDE; IDARUBICIN; MENOGARIL; MITOXANTRONE; NAVELBINE; OXANTHRAZOLE; PACLITAXEL; PIRAZOFURIN; UNINDEXED DRUG; VALRUBICIN; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; DRUG EXTRAVASATION; DRUG SAFETY; EXTRAVASATION; HUMAN; REVIEW; SYMPTOMATOLOGY;

EID: 0033959391     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500105     Document Type: Review

References (57)

1. Black R. Vein extravasation: A severe complication of I.V therapy. Parenterals. 1988;2:5-7.
2. Mateu J, Alzamora M, Fanco M. Needlestick injuries and hazardous drugs. Am J Health Syst Pharm. 1956;53:1038,1071.
3. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796-99.
4. Cox K, Stuart-Harris R, Abdini G, et al. Tlie management of cytotoxic-drug extravasation: Guide-lines drawn up by a working part)' for the Clinical Oncological Society of Australia. MedJAust. 1988;l48:185-89.
5. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev. 1990;4:4l-60.
6. Terry J, Baranowski L, Lonsway RA, et al., eds. Intravenous Therapy: Clinical Principles and Practice. Philadelphia, PA: W.B. Saunders; 1995:260-2,422-3-
7. Boyle DM, Engelking C. Vesicant extravasation: Myths and realities. Oncol Nurs Forum. 1995;22:57-67.
8. Fish LS. The prevention and extravasation of antineoplastic agents. Hospital Pharmacy Hotline. 1990;3:l-3-
9. Parashos PJ. A rational approach for the management of tissue extravasation due to antineoplastic drugs. MicroLink Update. April 1986;2:13-5.
10. Oncology Nursing Society Clinical Practice Committee. Cancer Chemotherapy Guidelines: Recommendations for the Management of Vesicant Extravasation, Ilypersensitivity, and Anaphylaxis. Philadelphia, PA: Oncology Nursing Press; 1992.
11. Rudolph R. Larson DL Etiology and treatment of chemotherapeutic agent extravasation injuries: A review. J Clin OJJcoJ.1987;5:l 116-26.
12. Ignoffo RJ, Friedman MA. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev. 1980;7:17-27.
13. Dorr RT. Pharmacologie management of vesicant chemotherapy extravasation. In: Dorr RT, Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994,109-18.
14. Wood LS, Gullo SM. IV vesicants: How to avoid extravasation. Am J Nurs. 1993; 93:42-6.
15. Zenk KE. Management of intravenous extravasations. Infusion. 1981;5:77-9.
16. Lokich JJ, Moore C. Drug extravasation in cancer chemotherapy [letter]. Ann Intern Mecl. 1986;104:124.
17. Moore C, Strong D, Childress J, et al. Surveillance of the patient receiving infusional cancer chemotherapy: Nursing role in recognition and management of catheterrelated complications. J Infus Chemothet: 1996;6:171-80.
18. Banerjee A, Brotherston TM, Lamberty BGH, et al. Cancer chemotherapy agentinduced perivenous extravasation injuries. Postgrad MedJ. 1987;63:5-9.
19. Lauvin R, Miglianico L, Hellegouarc HR. Skin cancer occurring 10 years after the extra vasation of doxorubicin.AF.£fw,gJJjVJeJ. 1995:332:754.
20. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety. 1995:12:245-55.
21. Shenaq SM, Abbase EA, Friedman JD. Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am. 1996:5:825-45-
22. Birdsall C, Naliboff AR. How do you manage chemotherapy extravasation Am J Nurs. 1988;88:228-30.
23. Smith R. Prevention and treatment of extravasation. Br J Paren Tber. 1985;6: 114-20.
24. Holmes BC. Administration of cancer chemotherapy agents. In: Dorr RT, Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994,57-94.
25. Jameson J, O'Donnell J. Guidelines for extravasation of intravenous drugs. Infnsion. 1983:7:157-61,165.
26. Hirsh JD, Conlon PF. Implementing guidelines for managing extravasation of antineoplastics. Am J Hasp Pbarm. 1983; 40:1516-19.
27. Flemmer L, Chan JSL. A pédiatrie protocol for management of extravasation injuries. Pediatr Ntirs. 1993;19:35558,424.
28. Wolfe CA, Linkewich JA. Preparation of guidelines for the avoidance and treatment of extravasation due to antineoplastic drugs. Hasp Pbarm. 1987;22:125-31.
29. Hankin FM, Louis DS. Extravasation of chemotherapeutic agents. Am Fam Physician. 198531:147-50.
30. Hessen JA. Protocol for treatment of vesicant antineoplastic extravasation. Hasp Phantt. 1989:24:705-9.
31. Dini D, Forno G, Gozza A, et al. Combined management in the treatment of epidoxorubicin extravasation. Support Care Cancer. 1995:3:150-2.
32. Dorr R, Sohle MJ, Lidclil JD, et ai. Mitomycin-C skin toxicity studies in mice: Reduced ulcération and altered pharmacokinetics with topical dimethyl sulfoxide.J Clin Oncol. 1986;4:1399-1404.
33. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study.J Clin Oncol. 1995;13:2851-55.
34. Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation.J Clin Oncol. 1988;6:1732-5.
35. Ludwig CU, Stoll H, Obrist R, et al. Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol. 1987;23:327-329.
36. Lawrence HJ, Goodnight SH. Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med. 1983;98:1025.
37. Alberts DS, Dorr RT. Case report: Topical DMSO for mitomycin-C induced skin ulcération. Oncol ffurs Forum. 1991;18:693-5.
38. Lawrence HJ.Walsh D, Zapotowski KA, et al. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Cbemother Pbannacol. 1989;23:3l6-8.
39. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Sitrg. 1985:75:397-402.
40. Olver IN, Schwarz MA. Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep. 1983;67:407-8.
41. McEvoy GK, Litvak K.Welsh OH, et al., CUS.AHFS 99 Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 1999.
42. Mosby's GenRx: no Complete Reference for Generic and Brand Dntgs. St. Louis, MO: Mosby Inc.; 1999.
43. DcpoCyt (cytarabine liposome injection) package insert. San Diego, CAJEmeryville, CA: DepoTech CorporationJChiron Therapeutics; April 1999.
44. Dezube BJ. Safety assessment: Doxil (doxorubicin HC1 liposome injection) in refractor)' AIDS-related Kaposi's sarcoma. Doxil Clinical Series. Menlo Park, CA: Sequus Pharmaceuticals; 1997,1-7.
45. Gabizon AA. Liposomal anthrac)'clines. Hcmatol Oticol Clin North Am. 1994;8: 431-50.
46. Davis ME, DeSantis D, Klemm K. A How sheet for follow-up after chemotherapy extravasation. Oticol Nnrs Forum. 1995;22: 979-83.
47. Amonafide. In: Dorr RT, Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 175-82.
48. Echinomycin. In: Dorr RT.Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994,416-9.
49. Esorubicin. In: Dorr RT, Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Linge; 1994, 439-43.
50. Piroxantrone. In: Dorr RT, Von Hoff DD, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994,791-4.
51. Kara M, Ross D. Severe soft tissue necrosis after extravasation of mitoxantrone: Case report. Can J Plast Surg. 1998;6:204-6.
52. Bailey WL, Crump RM. Taxol extravasation: A case report. Can Oticol Nurs J. 1997;7:96-9.
53. Bicher A, Levenback C, Burke TW, et al. Infusion site soft-tissue injury' after paclitaxel administration. Cancer. 1995;76:116-20.
54. Finley RS. Administration of cancer chemotherapy. In: Finlay RS, Balmer C, eds. Concepts in Oncology Therapeutics. 2nd edition. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 1998, 173-95.
55. Busulfex (busulfan) injection package insert. Minnetonka, MM: Orphan Medical; Februar)' 1999.
56. Berg D. Irinotecan hydrochloride: Drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. Oncol Nurs Forum. 1998;25:535-43.
57. Valstar (valrubicin) sterile solution for intravesical instillation package insert. Bedford, OHJRochester, NY: Ben Venue LaboratoriesJMedeva Pharmaceuticals, Inc.; June 1998.